Search Results - entry

2 Results Sort By:
COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2)
The coronavirus disease 2019 (COVID-19) is caused by a novel RNA enveloped coronavirus, SARS-CoV-2 when the virus enters human airway cells via an ACE2-mediated entry process. This entry pathway is facilitated by the cell surface heparan sulfate proteoglycan (HSPG), which enhances viral attachment to the cell surface. Researchers at NIDDK and NCATS...
Published: 10/28/2024   |   Inventor(s): Qi Zhang, Wei Zheng, Catherine Chen, Yihong Ye
Keywords(s): COVID-19, DB4BXX, ENTRY, HEPARAN, option, Sulfate-dependent, Targeting, therapeutic, viral
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Therapeutics
Synergistic Internal Ribosomal Entry Site (IRES)—MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development
Many members of the Flaviviridae family are emerging and reemerging human pathogens that have caused outbreaks of devastating and often fatal diseases and represent a serious public health problem on a global scale. There is no single attenuation strategy that exists which is sufficient to prepare a safe, efficacious and immunogenic live attenuated...
Published: 10/28/2024   |   Inventor(s): Konstantin Tsetsarkin, Alexander Pletnev
Keywords(s): Approach, ATTENUATION, DC1XXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, DD1XXX, DDXXXX, Development, DEXXXX, DXXXXX, ENTRY, FLAVIVIRUSES, INTERNAL, Live, Pnd, RIBOSOME, Site/microRNA-based, Synergistic, Vaccine, Zika
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Research Materials, Application > Vaccines